Emmaus Life Sciences, Inc. (EMMA)
USD 0.02
(-12.28%)
USD 0.02
(-12.28%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 35.17 Million USD | -27.05% |
| 2022 | 48.22 Million USD | -15.0% |
| 2021 | 56.73 Million USD | -4.29% |
| 2020 | 59.27 Million USD | -0.3% |
| 2019 | 59.45 Million USD | 1054.08% |
| 2018 | 5.15 Million USD | -15.49% |
| 2017 | 6.09 Million USD | 361.79% |
| 2016 | 1.32 Million USD | 132.78% |
| 2015 | 567.1 Thousand USD | -57.56% |
| 2014 | 1.33 Million USD | -4.71% |
| 2013 | 1.4 Million USD | 1019.07% |
| 2012 | 125.3 Thousand USD | -66.14% |
| 2011 | 370 Thousand USD | 55.79% |
| 2010 | 237.5 Thousand USD | -79.54% |
| 2009 | 1.16 Million USD | -55.92% |
| 2008 | 2.63 Million USD | -56.2% |
| 2007 | 6.01 Million USD | 5249.59% |
| 2006 | 112.39 Thousand USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 1097.00 USD | 3.3% |
| 2002 | 1062.00 USD | -66.31% |
| 2001 | 3152.00 USD | -35.37% |
| 2000 | 4877.00 USD | -51.23% |
| 1999 | 10 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 25.93 Million USD | -12.2% |
| 2024 Q1 | 29.54 Million USD | -16.02% |
| 2023 Q3 | 47.45 Million USD | -5.64% |
| 2023 FY | 35.17 Million USD | -27.05% |
| 2023 Q1 | 48.94 Million USD | 1.5% |
| 2023 Q2 | 50.28 Million USD | 2.74% |
| 2023 Q4 | 35.17 Million USD | -25.87% |
| 2022 FY | 48.22 Million USD | -15.0% |
| 2022 Q2 | 45.98 Million USD | -10.69% |
| 2022 Q1 | 51.49 Million USD | -9.24% |
| 2022 Q3 | 42.2 Million USD | -8.24% |
| 2022 Q4 | 48.22 Million USD | 14.27% |
| 2021 Q2 | 63.27 Million USD | 1.7% |
| 2021 FY | 56.73 Million USD | -4.29% |
| 2021 Q4 | 56.73 Million USD | -5.53% |
| 2021 Q3 | 60.05 Million USD | -5.09% |
| 2021 Q1 | 62.22 Million USD | 4.97% |
| 2020 Q2 | 56.25 Million USD | -14.76% |
| 2020 FY | 59.27 Million USD | -0.3% |
| 2020 Q1 | 65.99 Million USD | 10.99% |
| 2020 Q4 | 59.27 Million USD | -1.12% |
| 2020 Q3 | 59.94 Million USD | 6.57% |
| 2019 FY | 59.45 Million USD | 1054.08% |
| 2019 Q2 | 4.34 Million USD | 38.44% |
| 2019 Q3 | 56.48 Million USD | 1198.91% |
| 2019 Q4 | 59.45 Million USD | 5.27% |
| 2019 Q1 | 3.14 Million USD | -7.78% |
| 2018 Q4 | 3.4 Million USD | -33.89% |
| 2018 Q3 | 5.15 Million USD | 8.45% |
| 2018 Q2 | 4.75 Million USD | 4.82% |
| 2018 Q1 | 4.53 Million USD | -0.24% |
| 2018 FY | 5.15 Million USD | -15.49% |
| 2017 Q3 | 6.09 Million USD | 402.15% |
| 2017 FY | 6.09 Million USD | 361.79% |
| 2017 Q4 | 4.54 Million USD | -25.48% |
| 2017 Q2 | 1.21 Million USD | -50.04% |
| 2017 Q1 | 2.43 Million USD | -1.7% |
| 2016 Q4 | 2.47 Million USD | 87.27% |
| 2016 Q1 | 659.9 Thousand USD | -28.61% |
| 2016 FY | 1.32 Million USD | 132.78% |
| 2016 Q2 | 706.4 Thousand USD | 7.05% |
| 2016 Q3 | 1.32 Million USD | 86.88% |
| 2015 Q3 | 567.1 Thousand USD | 107.65% |
| 2015 FY | 567.1 Thousand USD | -57.56% |
| 2015 Q4 | 924.3 Thousand USD | 62.99% |
| 2015 Q2 | 273.1 Thousand USD | -39.81% |
| 2015 Q1 | 453.7 Thousand USD | -10.53% |
| 2014 Q2 | 197.3 Thousand USD | -78.65% |
| 2014 Q1 | 924.2 Thousand USD | 23.29% |
| 2014 Q4 | 507.1 Thousand USD | -62.05% |
| 2014 FY | 1.33 Million USD | -4.71% |
| 2014 Q3 | 1.33 Million USD | 577.19% |
| 2013 FY | 1.4 Million USD | 1019.07% |
| 2013 Q1 | 882.1 Thousand USD | -3.04% |
| 2013 Q4 | 749.6 Thousand USD | -46.54% |
| 2013 Q3 | 1.4 Million USD | 68.68% |
| 2013 Q2 | 831.3 Thousand USD | -5.76% |
| 2012 FY | 125.3 Thousand USD | -66.14% |
| 2012 Q4 | 909.8 Thousand USD | 626.1% |
| 2012 Q3 | 125.3 Thousand USD | -32.38% |
| 2012 Q2 | 185.3 Thousand USD | -73.71% |
| 2012 Q1 | 704.9 Thousand USD | 52.64% |
| 2011 Q3 | 370 Thousand USD | -72.85% |
| 2011 Q1 | 1.06 Million USD | 25.52% |
| 2011 FY | 370 Thousand USD | 55.79% |
| 2011 Q2 | 1.36 Million USD | 27.85% |
| 2011 Q4 | 461.8 Thousand USD | 24.81% |
| 2010 Q2 | 234.9 Thousand USD | -74.26% |
| 2010 FY | 237.5 Thousand USD | -79.54% |
| 2010 Q4 | 849.2 Thousand USD | 257.56% |
| 2010 Q1 | 912.5 Thousand USD | -55.8% |
| 2010 Q3 | 237.5 Thousand USD | 1.11% |
| 2009 Q1 | 1.17 Million USD | -26.03% |
| 2009 FY | 1.16 Million USD | -55.92% |
| 2009 Q4 | 2.06 Million USD | 77.84% |
| 2009 Q2 | 1.39 Million USD | 19.28% |
| 2009 Q3 | 1.16 Million USD | -16.88% |
| 2008 Q2 | 3.73 Million USD | -21.04% |
| 2008 Q1 | 4.72 Million USD | -11.78% |
| 2008 FY | 2.63 Million USD | -56.2% |
| 2008 Q4 | 1.58 Million USD | -39.89% |
| 2008 Q3 | 2.63 Million USD | -29.48% |
| 2007 Q2 | 6.6 Million USD | -0.88% |
| 2007 Q1 | 6.66 Million USD | 5832.38% |
| 2007 FY | 6.01 Million USD | 5249.59% |
| 2007 Q4 | 5.36 Million USD | -10.81% |
| 2007 Q3 | 6.01 Million USD | -9.06% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q3 | 117.81 Thousand USD | 0.0% |
| 2006 Q4 | 112.39 Thousand USD | -4.6% |
| 2006 FY | 112.39 Thousand USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | 969.3 Thousand USD | 576868.45% |
| 2004 Q1 | 168.00 USD | -84.69% |
| 2004 Q3 | - USD | -100.0% |
| 2003 Q1 | 1640.00 USD | 54.43% |
| 2003 Q2 | 1498.00 USD | -8.66% |
| 2003 Q3 | 669.00 USD | -55.34% |
| 2003 Q4 | 1097.00 USD | 63.98% |
| 2003 FY | 1097.00 USD | 3.3% |
| 2002 Q3 | 3117.00 USD | 82.28% |
| 2002 Q4 | 1062.00 USD | -65.93% |
| 2002 Q2 | 1710.00 USD | -40.65% |
| 2002 Q1 | 2881.00 USD | -8.6% |
| 2002 FY | 1062.00 USD | -66.31% |
| 2001 Q1 | 2751.00 USD | -72.49% |
| 2001 Q2 | 2942.00 USD | 6.94% |
| 2001 Q4 | 3152.00 USD | 129.24% |
| 2001 FY | 3152.00 USD | -35.37% |
| 2001 Q3 | 1375.00 USD | -53.26% |
| 2000 FY | 4877.00 USD | -51.23% |
| 2000 Q1 | 10 Thousand USD | 0.0% |
| 2000 Q2 | 10 Thousand USD | 0.0% |
| 2000 Q3 | 10 Thousand USD | 0.0% |
| 2000 Q4 | 10 Thousand USD | 0.0% |
| 1999 Q2 | 10 Thousand USD | 0.0% |
| 1999 Q3 | 10 Thousand USD | 0.0% |
| 1999 Q4 | 10 Thousand USD | 0.0% |
| 1999 FY | 10 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -1522800.433% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1696.507% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -233.324% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -6271.622% |
| Rebus Holdings, Inc. | 5000.00 USD | -703480.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 72.983% |
| Qrons Inc. | 420.00 USD | -8375852.381% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -4464.883% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -25.891% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -7220.464% |
| Skye Bioscience, Inc. | 11.94 Million USD | -194.621% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 9.442% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -387.26% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -45973.552% |
| SQZ Biotechnologies Company | 107.18 Million USD | 67.18% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -2356.579% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -48513.28% |
| Mesoblast Limited | 667.9 Million USD | 94.733% |
| Marizyme, Inc. | 22.01 Million USD | -59.795% |
| Genus plc | 1.02 Billion USD | 96.581% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -2489.828% |
| Pharming Group N.V. | 462.85 Million USD | 92.4% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -961.843% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -6949.349% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -5510.686% |
| ContraFect Corporation | 20.67 Million USD | -70.119% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -8911.799% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -9104.897% |
| IMV Inc. | 31.33 Million USD | -12.272% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -748.5% |
| MultiCell Technologies, Inc. | 126.22 USD | -27871077.309% |
| ONE Bio Corp. | 70.08 Million USD | 49.806% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -3643.685% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 72.625% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -8048.682% |
| Q BioMed Inc. | 3.51 Million USD | -900.678% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -13364.254% |
| Biomind Labs Inc. | 73.81 Thousand USD | -47555.753% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 92.118% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -2328.075% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -17.205% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -1180.944% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -5017.05% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -1251.377% |
| GB Sciences, Inc. | 103.44 Thousand USD | -33908.43% |
| Alpha Cognition Inc. | 2.45 Million USD | -1334.607% |
| HST Global, Inc. | 1526.00 USD | -2305207.995% |
| CSL Limited | 38.02 Billion USD | 99.907% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -3460.746% |
| Halberd Corporation | 10.13 Thousand USD | -347141.141% |
| Enzolytics Inc. | 361.7 Million USD | 90.274% |
| Agentix Corp. | 261.39 Thousand USD | -13358.331% |
| Resverlogix Corp. | 8.11 Million USD | -333.506% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -1773.336% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.226% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 26.253% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -5399.675% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -154322.545% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -293.099% |
| AVAX Technologies, Inc. | 7.37 Million USD | -376.864% |
| Zenith Capital Corp. | 7410.00 USD | -474650.337% |
| Genscript Biotech Corporation | 3.38 Billion USD | 98.961% |
| Ember Therapeutics, Inc. | 184.00 USD | -19118921.739% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -10831.741% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -13359.773% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -3691.0% |
| Kadimastem Ltd | 2.3 Million USD | -1426.813% |
| Helix BioMedix, Inc. | 3.02 Million USD | -1062.909% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 33.248% |
| BioStem Technologies, Inc. | 14.56 Million USD | -141.609% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -61515.932% |
| LadRx Corporation | 2.3 Million USD | -1424.298% |
| Cell Source, Inc. | 195.17 Thousand USD | -17924.707% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -9848.334% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -9848.334% |
| NovAccess Global Inc. | 62.24 Thousand USD | -56414.266% |
| Affymax, Inc. | 7.44 Million USD | -372.645% |
| Itoco Inc. | 1.4 Million USD | -2412.656% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -36676.19% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -33087.736% |
| Mobile Lads Corp. | 52.00 USD | -67651823.077% |
| CytoDyn Inc. | 11.13 Million USD | -215.903% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -24505.517% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -196650.559% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -9026.238% |
| SYBLEU INC | 330.46 Thousand USD | -10545.206% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -8492.357% |
| International Stem Cell Corporation | 5.39 Million USD | -552.672% |
| Bioxytran, Inc. | 137.63 Thousand USD | -25459.075% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -134.498% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -112.19% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -44430.38% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -3968.456% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -367.993% |
| Neutra Corp. | 2851.00 USD | -1233817.924% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -8.557% |
| PureTech Health plc | 693.97 Million USD | 94.931% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -335.864% |
| IXICO plc | 15.84 Million USD | -122.035% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -324.765% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 65.953% |
| CSL Limited | 38.02 Billion USD | 99.907% |
| Cellectis S.A. | 333.99 Million USD | 89.467% |